Hansa Biopharma AB (publ) – LSE:0RC7.L

Hansa Biopharma AB (publ) stock price today

SEK 84.7
Financial Health
0
1
2
3
4
5
6
7
8
9

Hansa Biopharma AB (publ) key metrics

Market Cap
 5.37B
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -16.08
Revenue
 165.88M
EBITDA
 -697.09M
Income
 -844.87M
Revenue Q/Q
 131.38%
Revenue Y/Y
 11.75%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -420.24%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Hansa Biopharma AB (publ) stock price history

Hansa Biopharma AB (publ) stock forecast

Hansa Biopharma AB (publ) financial statements

Profit Margin

Hansa Biopharma AB (publ) (LSE:0RC7.L): Profit margin
Jun 2023 36.65M -251.18M -685.32%
Sep 2023 22.83M -250.65M -1097.6%
Dec 2023 50.41M -124.45M -246.89%
Mar 2024 55.98M -218.57M -390.45%
0RC7.L income statement history

Debt to Assets

Hansa Biopharma AB (publ) (LSE:0RC7.L): Debt to assets
Jun 2023 1362523000 1.18B 86.63%
Sep 2023 1171048000 1.23B 105.31%
Dec 2023 1018041000 1.18B 116.49%
Mar 2024 830550000 1.20B 145.06%
0RC7.L balance sheet history

Cash Flow

Hansa Biopharma AB (publ) (LSE:0RC7.L): Cash Flow
Jun 2023 -181.98M -155K -1.78M
Sep 2023 -192.86M 0 -1.79M
Dec 2023 -172.94M 405K -2.19M
Mar 2024 -189.14M -116K -1.85M
0RC7.L cash flow history

Hansa Biopharma AB (publ) alternative data

Hansa Biopharma AB (publ)
Employees

Hansa Biopharma AB (publ) (LSE:0RC7.L): Employee count
Aug 2023 150
Sep 2023 162
Oct 2023 162
Nov 2023 162
Dec 2023 168
Jan 2024 168
Feb 2024 168
Mar 2024 168
Apr 2024 168
May 2024 166
Jun 2024 166
Jul 2024 166

Hansa Biopharma AB (publ) other data

Frequently Asked Questions (FAQ)

  • What's the price of Hansa Biopharma AB (publ) stock today?

    One share of Hansa Biopharma AB (publ) stock can currently be purchased for approximately $84.7.

  • When is Hansa Biopharma AB (publ)'s next earnings date?

    Unfortunately, Hansa Biopharma AB (publ)'s (0RC7.L) next earnings date is currently unknown.

  • Does Hansa Biopharma AB (publ) pay dividends?

    No, Hansa Biopharma AB (publ) does not pay dividends.

  • How much money does Hansa Biopharma AB (publ) make?

    Hansa Biopharma AB (publ) has a market capitalization of 5.37B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 13.22% to 134.09M US dollars.

  • What is Hansa Biopharma AB (publ)'s stock symbol?

    Hansa Biopharma AB (publ) is traded on the LSE under the ticker symbol "0RC7.L".

  • What is Hansa Biopharma AB (publ)'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Hansa Biopharma AB (publ)?

    Shares of Hansa Biopharma AB (publ) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Hansa Biopharma AB (publ) have?

    As Jul 2024, Hansa Biopharma AB (publ) employs 166 workers, which is 1% less then previous quarter.

  • When Hansa Biopharma AB (publ) went public?

    Hansa Biopharma AB (publ) is publicly traded company for more then 9 years since IPO on 22 Apr 2016.

  • What is Hansa Biopharma AB (publ)'s official website?

    The official website for Hansa Biopharma AB (publ) is hansabiopharma.com.

  • How can i contact Hansa Biopharma AB (publ)?

    Hansa Biopharma AB (publ) can be reached via phone at +46 46 16 56 70.

Hansa Biopharma AB (publ) company profile:

Hansa Biopharma AB (publ)

hansabiopharma.com
Exchange:

LSE

Full time employees:

135

Industry:

Biotechnology

Sector:

Healthcare

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

+46 46 16 56 70
PO Box 785
Lund, 220 07

:
:
: